Last reviewed · How we verify
carboplatin and liposomal doxorubicin
carboplatin and liposomal doxorubicin is a Small molecule drug developed by ARCAGY/ GINECO GROUP. It is currently in Phase 1 development. Also known as: carboplatin, liposomal doxorubicin, Myocet.
At a glance
| Generic name | carboplatin and liposomal doxorubicin |
|---|---|
| Also known as | carboplatin, liposomal doxorubicin, Myocet |
| Sponsor | ARCAGY/ GINECO GROUP |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- DIARRHOEA
- NAUSEA
- ALOPECIA
- FATIGUE
- VOMITING
- ARTHRALGIA
- CONSTIPATION
- ANAEMIA
- STOMATITIS
- MYALGIA
- RASH
- NEUTROPENIA
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients (PHASE2)
- A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer (PHASE3)
- Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) (PHASE3)
- Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) (PHASE2)
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- carboplatin and liposomal doxorubicin CI brief — competitive landscape report
- carboplatin and liposomal doxorubicin updates RSS · CI watch RSS
- ARCAGY/ GINECO GROUP portfolio CI
Frequently asked questions about carboplatin and liposomal doxorubicin
What is carboplatin and liposomal doxorubicin?
carboplatin and liposomal doxorubicin is a Small molecule drug developed by ARCAGY/ GINECO GROUP.
Who makes carboplatin and liposomal doxorubicin?
carboplatin and liposomal doxorubicin is developed by ARCAGY/ GINECO GROUP (see full ARCAGY/ GINECO GROUP pipeline at /company/arcagy-gineco-group).
Is carboplatin and liposomal doxorubicin also known as anything else?
carboplatin and liposomal doxorubicin is also known as carboplatin, liposomal doxorubicin, Myocet.
What development phase is carboplatin and liposomal doxorubicin in?
carboplatin and liposomal doxorubicin is in Phase 1.
What are the side effects of carboplatin and liposomal doxorubicin?
Common side effects of carboplatin and liposomal doxorubicin include DIARRHOEA, NAUSEA, ALOPECIA, FATIGUE, VOMITING, ARTHRALGIA.
Related
- Manufacturer: ARCAGY/ GINECO GROUP — full pipeline
- Also known as: carboplatin, liposomal doxorubicin, Myocet
- Compare: carboplatin and liposomal doxorubicin vs similar drugs
- Pricing: carboplatin and liposomal doxorubicin cost, discount & access